La Jolla Pharmaceutical CompanyFind Ratings Reports
LA JOLLA PHARMACEUTICAL CO's gross profit margin for the first quarter of its fiscal year 2021 has significantly increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the subsector when comparing revenue growth, but not when comparing net income growth. LA JOLLA PHARMACEUTICAL CO is extremely liquid. Currently, the Quick Ratio is 3.94 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.
During the same period, stockholders' equity ("net worth") has decreased by 17.26% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY21||Q1 FY20|
|Net Sales ($mil)||34.14||7.59|
|Net Income ($mil)||14.42||-8.59|
|Balance Sheet||Q1 FY21||Q1 FY20|
|Cash & Equiv. ($mil)||38.63||77.22|
|Total Assets ($mil)||89.59||118.21|
|Total Debt ($mil)||127.25||152.97|
|Profitability||Q1 FY21||Q1 FY20|
|Gross Profit Margin||85.17||-123.83|
|Return on Assets||-18.31||-79.02|
|Return on Equity||0.0||0.0|
|Debt||Q1 FY21||Q1 FY20|
|Share Data||Q1 FY21||Q1 FY20|
|Shares outstanding (mil)||27.45||27.28|
|Div / share||0.0||0.0|
|Book value / share||-2.63||-2.26|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||258369.0||287147.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well below both the S&P 500 average and the subsector average, indicating a discount.
|LJPC NM||Peers 69.82||LJPC NM||Peers 29.12|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
LJPC's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
LJPC's P/CF is negative making the measure meaningless.
|LJPC 17.14||Peers 18.12||LJPC NA||Peers 0.41|
Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.
LJPC is trading at a significant discount to its peers.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|LJPC NM||Peers 13.17||LJPC 79.43||Peers 150.58|
Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
LJPC's P/B is negative making this valuation measure meaningless.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, LJPC is expected to significantly trail its peers on the basis of its earnings growth rate.
|LJPC 1.65||Peers 1436.17||LJPC 128.43||Peers 1798.74|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
LJPC is trading at a significant discount to its subsector on this measurement.
Lower. A sales growth rate that trails the subsector implies that a company is losing market share.
LJPC significantly trails its peers on the basis of sales growth.